Chuanliang Cui News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chuanliang cui. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chuanliang Cui Today - Breaking & Trending Today

BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021

BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United States , Ligang Xing , Xiaolong Yan , Yunpeng Yang , Yong Ben , Baohui Han , Chuanliang Cui , Jeffrey Goh , Gabrielle Zhou , Esmo Io Congress , Therapeutic Development , Mirati Therapeutics Inc , Exchange Commission , Broad Clinical Program To Address Unmet Needs , Oncology Esmo Io Congress , European Society For Medical Oncology Immuno , Bristol Myers Squibb , European Society , Medical Oncology Immuno , Chief Medical Officer , Clinical Program , Address Unmet , Combination Therapies , Expand Clinical Benefit , Mirati Therapeutics , Paper Session ,

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Press release content from Business Wire. The AP news staff was not involved in its creation.
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
April 11, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Apr 11, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitor ....

United States , New Zealand , United Kingdom , Chuanliang Cui , Bristol Myers Squibb , Jeffrey Goh , Yong Ben , Beigene Ltd , Oncologist At Icon Cancer Centre , Mirati Therapeutics Inc , Exchange Commission , Tislelizumab Clinical Program , China National Medical Products Administration , American Association For Cancer Research , Amgen Inc , Mirati Therapeutics , American Association , Cancer Research , Annual Meeting , Chief Medical Officer , Metastatic Melanoma Refractory , Beijing Cancer Hospital , Medical Oncologist , Icon Cancer Centre , Biologics License Applications , Drug Evaluation ,